Home  |  About  |  PCSK9  |  News  |  Commentary  |  Trials  |  Videos  |  Resources  |  Contact FOURIER doesn't disappoint Amgen announces positive topline results Amgen has confirmed that the much-awaited FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) trial showed that treatment with the PCSK9 inhibitor evolocumab significantly reduced the risk of cardiovascular events in patients with clinical atherosclerotic cardiovascular disease on optimized statin therapy. PCSK9 Forum Editor Professor Henry Ginsberg (Columbia University, New York, USA) sums up the enthusiasm about these important results among the clinical community. Read the report here » Our popular therapeutic guide Third edition coming soon updated with the latest information discussing the biology and therapeutic potential of PCSK9 inhibition. Read online » Download now » Forward to colleagues »   Questions & Answers Read the full answer and other questions on the PCSK9 Forum » Like us on Facebook For the latest updates, PCSK9 news and analysis. Follow us on Twitter Hot topics, news and conference reports. YouTube Channel For videos, interviews and webcasts from leading experts. Educational Partners and Supporters Copyright PCSK9 Forum 2017. Please click here to unsubscribe from future mailings.